These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 27686050)
1. Herceptin-functionalized pure paclitaxel nanocrystals for enhanced delivery to HER2-postive breast cancer cells. Noh JK; Naeem M; Cao J; Lee EH; Kim MS; Jung Y; Yoo JW Int J Pharm; 2016 Nov; 513(1-2):543-553. PubMed ID: 27686050 [TBL] [Abstract][Full Text] [Related]
2. Enhanced delivery of Paclitaxel using electrostatically-conjugated Herceptin-bearing PEI/PLGA nanoparticles against HER-positive breast cancer cells. Yu K; Zhao J; Zhang Z; Gao Y; Zhou Y; Teng L; Li Y Int J Pharm; 2016 Jan; 497(1-2):78-87. PubMed ID: 26617314 [TBL] [Abstract][Full Text] [Related]
3. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells. Zhang F; Wang X; Xu X; Li M; Zhou J; Wang W Eur J Pharm Sci; 2016 Sep; 92():11-21. PubMed ID: 27343697 [TBL] [Abstract][Full Text] [Related]
5. The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles. Lee AL; Wang Y; Cheng HY; Pervaiz S; Yang YY Biomaterials; 2009 Feb; 30(5):919-27. PubMed ID: 19042015 [TBL] [Abstract][Full Text] [Related]
6. Antibody-drug nanoparticle induces synergistic treatment efficacies in HER2 positive breast cancer cells. Abedin MR; Powers K; Aiardo R; Barua D; Barua S Sci Rep; 2021 Apr; 11(1):7347. PubMed ID: 33795712 [TBL] [Abstract][Full Text] [Related]
7. Surface modification of docetaxel nanocrystals with HER2 antibody to enhance cell growth inhibition in breast cancer cells. Choi JS; Park JS Colloids Surf B Biointerfaces; 2017 Nov; 159():139-150. PubMed ID: 28783505 [TBL] [Abstract][Full Text] [Related]
8. Herceptin-conjugated paclitaxel loaded PCL-PEG worm-like nanocrystal micelles for the combinatorial treatment of HER2-positive breast cancer. Peng J; Chen J; Xie F; Bao W; Xu H; Wang H; Xu Y; Du Z Biomaterials; 2019 Nov; 222():119420. PubMed ID: 31445322 [TBL] [Abstract][Full Text] [Related]
9. Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy. Eloy JO; Petrilli R; Chesca DL; Saggioro FP; Lee RJ; Marchetti JM Eur J Pharm Biopharm; 2017 Jun; 115():159-167. PubMed ID: 28257810 [TBL] [Abstract][Full Text] [Related]
10. Functionalized nanoscale β-1,3-glucan to improve Her2+ breast cancer therapy: In vitro and in vivo study. Nasrollahi Z; Mohammadi SR; Mollarazi E; Yadegari MH; Hassan ZM; Talaei F; Dinarvand R; Akbari H; Atyabi F J Control Release; 2015 Mar; 202():49-56. PubMed ID: 25597638 [TBL] [Abstract][Full Text] [Related]
11. Dual-Targeted Delivery of Nanoparticles Encapsulating Paclitaxel and Everolimus: a Novel Strategy to Overcome Breast Cancer Receptor Heterogeneity. Houdaihed L; Evans JC; Allen C Pharm Res; 2020 Jan; 37(3):39. PubMed ID: 31965330 [TBL] [Abstract][Full Text] [Related]
12. Specific drug delivery efficiently induced human breast tumor regression using a lipoplex by non-covalent association with anti-tumor antibodies. Lin YL; Tsai NM; Chen CH; Liu YK; Lee CJ; Chan YL; Wang YS; Chang YC; Lin CH; Huang TH; Wang CC; Chi KH; Liao KW J Nanobiotechnology; 2019 Feb; 17(1):25. PubMed ID: 30728015 [TBL] [Abstract][Full Text] [Related]
13. Comparison of three different conjugation strategies in the construction of herceptin-bearing paclitaxel-loaded nanoparticles. Yu K; Zhou Y; Li Y; Sun X; Sun F; Wang X; Mu H; Li J; Liu X; Teng L; Li Y Biomater Sci; 2016 Aug; 4(8):1219-32. PubMed ID: 27367271 [TBL] [Abstract][Full Text] [Related]
14. Improving systemic circulation of paclitaxel nanocrystals by surface hybridization of DSPE-PEG2000. Wang D; Wang Y; Zhao G; Zhuang J; Wu W Colloids Surf B Biointerfaces; 2019 Oct; 182():110337. PubMed ID: 31306829 [TBL] [Abstract][Full Text] [Related]
15. Multicomponent Conjugates of Anticancer Drugs and Monoclonal Antibody with PAMAM Dendrimers to Increase Efficacy of HER-2 Positive Breast Cancer Therapy. Marcinkowska M; Stanczyk M; Janaszewska A; Sobierajska E; Chworos A; Klajnert-Maculewicz B Pharm Res; 2019 Sep; 36(11):154. PubMed ID: 31482205 [TBL] [Abstract][Full Text] [Related]
16. l-Peptide functionalized dual-responsive nanoparticles for controlled paclitaxel release and enhanced apoptosis in breast cancer cells. Niu S; Bremner DH; Wu J; Wu J; Wang H; Li H; Qian Q; Zheng H; Zhu L Drug Deliv; 2018 Nov; 25(1):1275-1288. PubMed ID: 29847177 [TBL] [Abstract][Full Text] [Related]
17. Herceptin conjugated PLGA-PHis-PEG pH sensitive nanoparticles for targeted and controlled drug delivery. Zhou Z; Badkas A; Stevenson M; Lee JY; Leung YK Int J Pharm; 2015 Jun; 487(1-2):81-90. PubMed ID: 25865568 [TBL] [Abstract][Full Text] [Related]
18. Silver nanoparticles functionalized Paclitaxel nanocrystals enhance overall anti-cancer effect on human cancer cells. Muhammad N; Zhao H; Song W; Gu M; Li Q; Liu Y; Li C; Wang J; Zhan H Nanotechnology; 2021 Feb; 32(8):085105. PubMed ID: 33197899 [TBL] [Abstract][Full Text] [Related]
19. Docetaxel-loaded nanostructured lipid carriers functionalized with trastuzumab (Herceptin) for HER2-positive breast cancer cells. Varshosaz J; Davoudi MA; Rasoul-Amini S J Liposome Res; 2018 Dec; 28(4):285-295. PubMed ID: 28826287 [TBL] [Abstract][Full Text] [Related]
20. Biological evaluation of a novel Herceptin-platinum (II) conjugate for efficient and cancer cell specific delivery. Huang R; Sun Y; Zhang XY; Sun BW; Wang QC; Zhu J Biomed Pharmacother; 2015 Jul; 73():116-22. PubMed ID: 26211591 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]